Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV001286485 | SCV001473067 | likely benign | Telangiectasia, hereditary hemorrhagic, type 5 | 2020-07-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001286485 | SCV001727173 | benign | Telangiectasia, hereditary hemorrhagic, type 5 | 2025-01-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002339711 | SCV002619038 | benign | Cardiovascular phenotype | 2022-02-11 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003973183 | SCV004790976 | benign | GDF2-related disorder | 2019-06-26 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |